Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.47 |
| ▸ | AURKA | O14965 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 9/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 9/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23642304 | 0.79 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL16123821 | 0.77 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL2923653 | 0.76 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL17229680 | 0.73 | CCNA2 (0.48) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL12057801 | 0.73 | CCNA2 (0.61) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL19831854 | 0.73 | MAPK1 (0.45) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL2922187 | 0.72 | CCNA2 (0.67) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL20033638 | 0.70 | AURKA (0.35) | CCNA2CDK2CCNA1AURKARBP4 | |
| SCHEMBL5720802 | 0.69 | BRD4 (0.62) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL2913589 | 0.69 | CCNA2 (0.63) | CCNA2CDK2CCNA1AURKAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913746-B2 | Substituted 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913746-B2 | Substituted 4-phenylpiperidines, their preparation and use | HRH4, HRH3, HRH2 | CCNA2 1032/4885CDK2 753/4885CCNA1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.